EGFR and non-small cell lung carcinoma: The studies showed that the patients of EGFR T790M-mutant NSCLC with central nervous system (CNS) metastases progressed on first- or second-generation EGFR-TKI and after osimertinib therapy had a high disease control rate (DCR) and objective remission rate (ORR) (13), and prolonged progression-free survival (PFS) (14, 15), since osimertinib has greater penetration of the blood–brain barrier and higher brain exposure compared with other EGFR-TKIs (16).